With investments worth USD 150 million…SCZONE’s chairman witnesses the groundbreaking of the “GENNVAX” vaccines and pharmaceuticals plant

Mr. Waleid Gamal El-Dien, Chairman of the General Authority for Suez Canal Economic Zone (SCZONE), witnessed today the groundbreaking ceremony of the GENNVAX vaccines and biological pharmaceuticals plant in the Sokhna Industrial Zone. The project is established on an area of 50,000 m², with total investments amounting to USD 150 million, and is the largest fully integrated facility in Egypt for producing vaccines and serums, covering the production of 29 vaccines and serums. The project has obtained the Golden License in recognition of its strategic importance.

Mr. Waleid Gamal El-Dien highlighted that the GENNVAX project represents a qualitative leap in the localization of Egypt’s medical and pharmaceutical industries, supporting national efforts to enhance self-sufficiency in vaccines and biological products. He added that the project aligns with SCZONE’s industrial localization plan, which aims to reduce reliance on imports and localize priority industries, particularly in the healthcare and pharmaceutical sectors.

It is worth noting that SCZONE places a strong emphasis on the pharmaceutical and medical supplies sector, allocating 4 million square meters in the Sokhna Industrial Zone for this industry. SCZONE hosts several leading projects, including Ateco Pharma for intravenous solutions with investments nearing EGP 1 billion; BMEC Imaging – Egypt for advanced medical devices with investments of USD 4.5 million; Arab API’s multi-purpose active pharmaceutical ingredients plant with investments of around USD 120 million in partnership with SCZONE’s investment arm (SCZONE Istithmar Company); in addition to the IDI pharmaceutical plant in East Port Said Industrial Zone, reinforcing SCZONE’s strategy to localize healthcare industries.